Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for cancer patients: drug may shield ears from chemo damage

NCT ID NCT07364747

Prevention Sponsor: Siriraj Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether acetylcysteine, a drug often used for other purposes, can prevent hearing loss caused by cisplatin chemotherapy. About 40 adults receiving high-dose cisplatin will get either acetylcysteine or a placebo after each chemo session. Researchers will measure hearing changes over time to see if the drug offers protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acetylcysteine (N-acetylcysteine)
What this could lead to
If it works, this could offer a simple way to prevent permanent hearing loss in patients receiving cisplatin chemotherapy.
What could go wrong
This is a small, early-phase trial with only 40 participants. The results may not apply to all patients, and acetylcysteine might not provide significant protection or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 18 and 70 years * Patients scheduled to receive high-dose cisplatin-based chemotherapy regimens with a projected cumulative cisplatin dose of \> 200 mg/m2 and each dose \> 50 mg/m2 * Patients may receive concurrent chemotherapy with non-ototoxic agents * Patients may receive concurrent radiation therapy to the skull base, provided the radiation dose does not exceed the toxic threshold for ototoxicity * Patients receiving an appropriate antiemetic regimen consisting of Olanzapine or Neurokinin-1 (NK1) receptor antagonists * Patients receiving medical treatment at Siriraj Hospital. Exclusion Criteria: * Patients diagnosed with Nasopharyngeal Carcinoma (CA nasopharynx). * Patients with a history of head and neck radiation therapy where the radiation dose to the cochlea exceeded 9 Gy or the dose to the eustachian tube exceeded 50 Gy on both sides. * Patients who have received N-acetylcysteine (NAC) within 2 weeks prior to the start of the study. * Patients who have received other ototoxic drugs within 2 weeks prior to or during the study, including but not limited to: Aminoglycoside antibiotics, Vancomycin, Loop diuretics (e.g., Furosemide), High-dose Aspirin, Antimalarial drugs (e.g., Quinine) \- Patient with a known allergy or hypersensitivity to acetylcysteine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cisplatin-induced ototoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hearing Loss, Sensorineural Ototoxicity sensorineural hearing loss disorder toxic labyrinthitis X-linked mixed hearing loss with perilymphatic gusher platinum-induced ototoxicity prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cisplatin-induced ototoxicity Ototoxicity Ototoxicity, drug-induced Sensorineural hearing loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    RECRUITING

    Bangkok, Bangkoknoi, 10700, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.